Special Issue

Understanding the Complexities of Anticancer Drugs Resistance

Message from the Guest Editors

Anticancer drug resistance is a major challenge in cancer therapy and significantly impacts patient outcomes. Genetic mutations play a pivotal role in drug resistance. These mutations can affect drug targets, drug metabolism, and DNA repair mechanisms, rendering the drugs ineffective. Furthermore, some mutations can activate alternative signaling pathways that bypass the drugs' intended targets. The tumor microenvironment can also contribute to drug resistance by providing a protective niche for cancer cells. Additionally, the tumor microenvironment can create physical barriers, such as a dense extracellular matrix, limiting drug penetration into the tumor. Understanding the mechanisms of drug resistance can drive the development of effective cancer treatments, including new drugs, combination therapies, and personalized medicine approaches. In this Special Issue of Cancers, we welcome original research articles or comprehensive reviews focusing on the complexities of anticancer drug resistance, including the mechanisms involved, the factors contributing to drug resistance, and the strategies to overcome drug resistance.

Guest Editors

Dr. Mariarosaria Conte

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy

Dr. Nunzio Del Gaudio

Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Via L. De Crecchio 7, 80138 Naples, Italy

Deadline for manuscript submissions

30 December 2025

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/184957

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)